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Abstract
Background and Purpose: The targeting of therapeutics is a promising approach for the development of new cancer
treatments that seek to reduce the devastating side effects caused by the systemic administration of current drugs. This
study evaluates a fusion protein developed as an enzyme prodrug therapy targeted to the tumor vasculature. Cytotoxicity
would be localized to the site of the tumor using a protein fusion of purine nucleoside phosphorylase (PNP) and annexin V.
Annexin V acts as the tumor-targeting component of the fusion protein as it has been shown to bind to phosphatidylserine
expressed externally on cancer cells and the endothelial cells of the tumor vasculature, but not normal vascular endothelial
cells. The enzymatic component of the fusion, PNP, converts the FDA-approved cancer therapeutic, fludarabine, into a more
cytotoxic form. The purpose of this study is to determine if this system has a good potential as a targeted therapy for breast
cancer.
Methods: A fusion of E. coli purine nucleoside phosphorylase and human annexin V was produced in E. coli and purified.
Using human breast cancer cell lines MCF-7 and MDA-MB-231 and non-confluent human endothelial cells grown in vitro,
the binding strength of the fusion protein and the cytotoxicity of the enzyme prodrug system were determined. Endothelial
cells that are not confluent expose phosphatidylserine and therefore mimic the tumor vasculature.
Results: The purified recombinant fusion protein had good enzymatic activity and strong binding to the three cell lines.
There was significant cell killing (p,0.001) by the enzyme prodrug treatment for all three cell lines, with greater than 80%
cytotoxicity obtained after 6 days of treatment.
Conclusion: These results suggest that this treatment could be useful as a targeted therapy for breast cancer.
Citation: Krais JJ, De Crescenzo O, Harrison RG (2013) Purine Nucleoside Phosphorylase Targeted by Annexin V to Breast Cancer Vasculature for Enzyme Prodrug
Therapy. PLoS ONE 8(10): e76403. doi:10.1371/journal.pone.0076403
Editor: Matthew Bogyo, Stanford University, United States of America
Received March 14, 2013; Accepted August 26, 2013; Published October 3, 2013
Copyright:  2013 Krais et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a grant from the Oklahoma Center for the Advancement of Science and Technology Health Research Program (grant
number HR11-210; www.ok.gov/ocast) and by funding from the School of Chemical, Biological and Materials Engineering at the University of Oklahoma (www.
cbme.ou.edu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rharrison@ou.edu
Introduction
Fludarabine (9-b-D-arabinofuranosyl-2-fluoroadenine 59-mono-
phosphate, 2-Fluoro-ara-AMP, F-ara-AMP), a cytotoxic purine
nucleoside analogue, is an approved treatment for chronic
lymphocytic leukemia [1,2,3,4]. Fludarabine has undergone
numerous clinical trials for treatment of both solid tumors and
leukemia; however success was hindered by dose limiting factors
including myelosuppression and neurotoxicity [4,5].
More recently, fludarabine has become the subject of study as
the prodrug for enzyme prodrug systems as therapies for cancers
such as glioma [6], prostate [7,8], bladder [9], and liver [10]. The
Escherichia coli enzyme purine nucleoside phosphorylase (PNP)
cleaves the ribose-1-phosphate group from fludarabine, resulting
in 2-fluoroadenine [11,12] which inhibits protein, RNA, and DNA
synthesis [13]. Fludarabine is not a substrate for the human PNP.
2-fluoroadenine toxicity to cancer cells occurs at a concentration
several orders of magnitude below that required for the same effect
from fludarabine [14], which allows for the systemic administra-
tion of fludarabine significantly below problematic levels while
improving the cytotoxic effect at the site of the tumor. In vivo PNP
gene delivery studies used intraperitoneal fludarabine doses
ranging from 37.5 mg/kg/day [7,10] to 450 mg/kg/day [15] in
mouse models. Minimal effect was attained by fludarabine alone,
but results were positive with the conversion to 2-fluoroadenine by
the enzyme prodrug therapies. No signs of systemic toxicity or
negative side effects were reported at these doses in either the
groups with fludarabine or fludarabine with PNP. One advantage
of this enzyme prodrug therapy is that there is a significant
bystander effect of the 2-fluoroadenine generated against both
proliferating and non-proliferating cells [13]. The bystander effect
results from the ability of 2-fluoroadenine to freely diffuse across
cell membranes, eliminating the need for PNP to be present in
each individual cell. This property helps to alleviate transfection
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efficiency problems of studies using suicide gene-directed enzyme
prodrug therapies (GDEPT) [8] and viral-directed enzyme
prodrug therapies (VDEPT) [6,7,10].
An alternative enzyme prodrug approach is to target the PNP
enzyme to the tumor with a targeting moiety. We have created a
fusion protein of E. coli PNP and human annexin V (AV), referred
to as PNP-AV. Annexin V binds to phosphatidylserine (PS)
expressed externally on tumor cells [16,17,18] and endothelial
cells of tumor vasculature, but not normal vascular endothelial
cells [19,20]. We have used other enzymes fused to annexin V,
and the resulting fusion proteins have been shown to maintain
binding properties and successfully target breast cancer cells
[21,22]. This approach to an enzyme prodrug system allows for
systemic administration of the fusion protein, with accumulation of
PNP in the tumor as a result of AV targeting of the tumor
vasculature and cancer cells. After clearance of PNP-AV from the
bloodstream, fludarabine would be administered systemically so
that 2-fluoroadenine is generated at the surface of the tumor
vasculature endothelial cells. The 2-fluoroadenine generated
would be expected to have a cytotoxic effect on the endothelial
cells and tumor cells, as it would be carried by permeation and
diffusion across the vascular wall. Fludarabine is not a substrate of
human nucleoside phosphorylases [11], so the conversion to 2-
fluoroadenine will not occur in normal tissue. The mechanism of
treatment is summarized in Fig. 1.
In the present study, the objective was to produce and evaluate
the efficacy in vitro of a PNP-AV fusion protein in the context of an
enzyme prodrug therapy for the treatment of breast cancer.
Protein production was successful, and the binding stability and
cytotoxicity of the PNP-AV enzyme prodrug therapy were
characterized for estrogen receptor-positive breast cancer MCF-
7 cells, estrogen receptor-negative breast cancer MDA-MB-231
cells (a triple-negative breast cancer), and endothelial HAAE-1
cells grown under conditions to mimic the tumor vasculature.
Materials and Methods
Construction of Recombinant Expression Plasmid
The PNP gene was provided by Dr. Joanne Turnbull of the
Department of Chemistry and Biochemistry of Concordia
University (Montreal, Canada). The AV gene was obtained from
Dr. Stuart Lind of the University of Colorado (Denver, CO). Both
genes were amplified separately with the Expand High Fidelity
PCR system from Roche Applied Sciences (Madison, WI). The
oligonucleotide PCR primers were synthetically produced by
Integrated DNA Technologies (Coralville, IA) and are displayed
below. The bold regions on the primers indicate the sequences
complementary to the genes. BamHI restriction enzyme sites are
shown as the boxed regions with the cut sites indicated. The
underlined segment in the PNP antisense primer is a linker region.
PNP gene sense primer:
59-GAC GAC GAC AAG ATG CCC GCT ACC CCA CAC
ATT AAT GCA G- 39
PNP gene antisense primer:
59-CGC G|GA TCC AGA ACC GGA GCC CTC TTT ATC
GCC CAG CAG AAC-39
Annexin V sense primer:
59-CGC G|GA TCC GCA CAG GTT CTC AGA GGC-39
Annexin V antisense primer:
59-GA GGA GAA GCC CGG TTA GTC ATC TTC TCC
ACA GAG C-39
The PCR products were purified using a QIAquick PCR
purification kit (Qiagen, Valencia, CA) and separately digested
with BamHI restriction enzyme (New England Biolabs, Ipswich,
MA). The digested genes were purified and ligated with T4 DNA
Figure 1. PNP-AVmechanism of action. Fludarabine is converted in serum to a dephosphorylated form by a 59nucleotidase [37]. PNP attached to
the cell surface via annexin V and phosphatidylserine binding then cleaves the ribose-1-phosphate group, resulting in 2-fluoroadenine [11,12]. The
freely diffusible molecule enters the cell and inhibits protein, RNA, and DNA synthesis [13]. Nucelotide-specific membrane transport carriers transport
the dephosphorylated form across the cell membrane, where it is then phosphorylated into a cytotoxic triphosphate [3,37].
doi:10.1371/journal.pone.0076403.g001
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ligase (New England Biolabs). The fusion gene was amplified via
PCR with the following sense and antisense primers:
Fusion gene sense primer:
59-CGC T|CT AGA ATG GCT ACC CCA CAC ATT AAT
GCA G-39
Fusion gene antisense primer:
59-CGC C|TCGAG CGG ACC CTG GAA CAG AAC TTC CAG
GTC ATC TTC TCC ACA GAG CAG C-39
The bold regions indicate the complementary sequences for the
start of the PNP gene for the sense primer and the end of the AV
gene on the antisense primer. Restriction enzyme sites were
incorporated, shown as the boxed regions with the cut site
indicated. The sense strand site is for Xba1 and the antisense
strand site is for Xho1. The antisense strand also includes a
cleavage site for the protease HRV-3C, shown in italics, to allow
for separation of the protein from the C-terminal His-tag using
immobilized metal affinity column chromatography (IMAC).
The PCR products were again purified using a QIAquick PCR
purification kit, run on an agarose gel, and extracted with a
QIAquick gel extraction kit from Qiagen. A restriction enzyme
digest was performed on the purified PNP-AV gene and pET 303/
CT-His vector (Invitrogen, Grand Island, NY) with Xho1 and
Xba1 (New England Biolabs). Ligation was performed with T4
DNA ligase. Plasmids were sent to Oklahoma Medical Research
Foundation (Oklahoma City, OK) for sequence verification
following transformation and culture of NovaBlue Gigasingles
competent cells (EMD Chemicals, Gibbstown, NJ). E. coli
BL21(DE3) cells (EMD Chemicals) were then transformed and
cultured for the protein expression.
Recombinant PNP-AV Expression and Purification
Recombinant PNP-AV was produced from a 1 liter culture of
BL21(DE3) cells and purified using IMAC with immobilized Ni2+,
according to the procedure of Zang et al. [23]. The fusion protein,
collected in the IMAC elution, was incubated with HRV-3C
protease to cleave the His-tag from the protein. A second IMAC
was performed to remove the protease, which also has a His-tag
for separation purposes, and uncleaved PNP-AV. Samples were
analyzed using SDS-PAGE with Coomassie blue staining [24],
and purity was determined with a densitometric analysis
performed with ImageJ software.
Determination of Protein Content and Enzyme Activity
Assay
The Bradford assay (Bio-Rad, Hercules, CA) with bovine serum
albumin standards was used for determination of protein content.
PNP activity was determined according to the quality control
procedure from Sigma [25]. The assay was performed with a
300 mL reaction volume of 90 mM potassium phosphate mono-
basic at pH 7.4, 0.25 mM inosine, 0.1 U xanthine oxidase, and
PNP enzyme with tests performed at 1.7 mg/ml and 0.17 mg/ml.
All chemicals were obtained for the PNP activity assay from
Sigma-Aldrich (St. Louis, MO). Absorbance at 293 nm was
measured every 7 seconds for 5 minutes with a Bio-Tek Synergy
HT microtiter plate reader (Winooski, VT), and the slope was
determined. The change in absorbance per min for a blank sample
was subtracted from the change in absorbance per min of the PNP
sample and divided by 12 (the millimolar extinction coefficient of
uric acid, a product of the xanthine oxidase catalyzed reaction)
and by the concentration of PNP to obtain a result in U/mg. One
unit (U) is defined as the quantity of enzyme required for the
phosphorolysis of 1.0 mmol of inosine to hypoxanthine and ribose
1-phosphate per minute at pH 7.4 and 25uC.
Cell Culture
Human breast cancer cell lines MDA-MB-231 and MCF-7
were obtained from American Type Culture Collection (Manassas,
VA), and human HAAE-1 aortic endothelial cells were from
Coriell Cell Repositories (Camden, NJ). Cell lines were acquired
within the past year, expanded, and multiple aliquots were frozen
in liquid nitrogen. No cells were used beyond the sixth passage. All
cells were maintained in medium containing 10% FBS, penicillin
(100 U/ml), and streptomycin (100 mg/ml). MDA-MB-231 cells
were grown in Leibovitz’s L-15 medium supplemented with 2 mM
L-glutamine at 37uC with no additional CO2, as recommended by
the ATCC. MCF-7 cells were cultured in Eagle’s minimum
essential medium containing Earle’s balanced salt solution, non-
essential amino acids, 2 mM L-glutamine, 1 mM sodium pyru-
vate, 1.5 g/L sodium bicarbonate and supplemented with
0.01 mg/ml human insulin. HAAE-1 cells were grown in flasks
and plates coated with 0.1% gelatin in F-12 K medium with
2 mM L-glutamine and 1.5 g/L sodium bicarbonate and supple-
mented with 0.03 mg/ml endothelial cell growth supplement and
0.1 mg/ml heparin. MCF-7 and HAAE-1 cells were grown at
37uC with 5% CO2.
Protein Binding Strength and Stability Assays
The dissociation constant to characterize binding of PNP-AV to
cells was determined as previously described [21]. This procedure
involves fixing the cells with 0.25% glutaraldehyde when they are
80–85% confluent, followed by incubating with biotinylated PNP-
AV and then washing. Bound PNP-AV is quantitated by
incubation with streptavidin-horseradish peroxidase, washing,
incubation with the chromogenic substrate O-phenylenediamine
and hydrogen peroxide, and measurement of absorbance at
450 nm. At each concentration of PNP-AV, the specific binding
was obtained by subtracting the non-specific binding (no CaCl2
present, 5 mM EDTA added) from the total binding (2 mM
CaCl2 added).
The stability of binding of PNP-AV to cells was determined as
previously described [21]. In this procedure, the Alamar Blue
assay [26] was performed as described in the cytotoxicity methods
section on separate sets of cells at 0, 1, 2, and 3 days to determine
cell viability, followed by fixing the cells and a determination of the
binding.
Binding Visualization
MCF-7 cells were grown on a coverslip and fixed at 80–85%
confluence according to the procedure for determining binding
strength. Fixation of cells with glutaraldehyde preserves cell
morphology while allowing the exposure of membrane binding
sites [27]. Afterwards, the cells were incubated at 37uC for 1 h
with biotinylated PNP-AV in growth medium with 2 mM Ca2+.
After washing, streptavidin-conjugated green Alexa Fluor 488
(Invitrogen) was added to the cells at 5 mg/ml for 30 min in order
to visualize biotinylated PNP-AV on the membrane surface
(streptavidin does not internalize into formerly viable cells after
fixation [28]). Cells were counterstained with 5 mg/ml Hoechst
33258 blue dye (Sigma-Aldrich) for nucleic acids for 30 min and
with 1 mg/ml CellMask Deep Red plasma membrane stain
(Invitrogen) using three 5 min incubations followed by washes.
The coverslip was attached to the slide with fluoro-gel with TES
buffer (Fisher Scientific, Hampton, NH). Slides were viewed
immediately following preparation with a Leica Microsystems SP8
confocal laser scanning microscope (Buffalo Grove, IL) in both the
x-y and x-z planes.
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In vitro Cytotoxicity
The cytotoxicity assays were performed over 6 days as two 3-
day cycles in 24-well plates under standard culture conditions with
calcium supplemented medium (2 mM Ca2+). On first day of each
cycle, day 0 and day 3, cells were incubated with 100 nM PNP-AV
for 2 h at 37uC. The plates were washed, and medium containing
varying concentrations of fludarabine (VWR, Radnor, PA) was
added. A control of fludarabine with no fusion protein and a
control of 2-fluoroadenine (Thermo Fisher Scientific, Waltham,
MA) were also included in the study. The medium containing
fludarabine or 2-fluoroadenine was replaced daily for the two
subsequent days of each cycle. An Alamar Blue assay was
performed to determine viability on days 0, 2, 4, and 6 with a 4-
hour incubation of cells at 37uC with 10% Alamar Blue reagent
(Invitrogen). Fluorescence was measured using a mictotiter plate
reader with an excitation wavelength of 530 nm and emission
wavelength of 590 nm after the solutions had been transferred to
an opaque 96-well plate.
Data Analysis
Assays were performed in triplicate and a one-way ANOVA
with a Tukey-Kramer multiple comparisons test was used with the
cytotoxicity analysis. Prism 5 software (GraphPad, La Jolla, CA)
was used to perform the calculations.
Results
Protein Expression and Purification
Cultures have yielded an average of 60 mg fusion protein per
liter of culture. The size of the PNP-AV monomers was confirmed
with SDS-PAGE to be 65 kDa as expected based on the known
monomeric PNP size of 26 kDa [29,30], AV size of 36 kDa, and
amino acid linker size of 3 kDa. Densitometric analysis deter-
mined a purity of .93%. The activity of PNP was determined to
be 35 U/mg PNP-AV. Models of the fusion protein and both
components are shown in Fig. 2.
Binding Strength and Stability
A typical equilibrium binding result is shown in Fig. 3 for the
binding of PNP-AV to MCF-7 breast cancer cells. The non-
specific binding, obtained in the absence of Ca+2, is subtracted
from the total binding to obtain the specific binding. We
previously determined that endothelial cells that are not confluent
when cultured in vitro expose PS [22]; therefore hydrogen peroxide
was not used to induce exposure of PS. It has been reported that
cancer cells express PS in vitro [16,17,18]. The dissociation
constant (Kd) for each cell line was obtained from the specific
binding data using Prism 5 software to give the results shown in
Table 1. The Kd values, which are all below 100 pM, indicate that
the binding of PNP-AV to these cells is relatively strong. The
binding strength assay was also performed with endothelial cells
that were confluent, and no Kd value could be obtained since the
specific binding was indistinguishable from the non-specific
binding.
PNP-AV binding per cell was studied over 3 days for the three
cell lines to determine the stability of binding. The binding assay
data (absorbance at 450 nm) was divided by the Alamar Blue
fluorescence data for cell viability (relative fluorescence at 530 nm
excitation, 590 emission) (Fig. 4). Initially, the endothelial cells and
MDA-MB-231 cancer cells had similar amounts of binding, while
the amount for MCF-7 cells was less. For all three cell lines, the
binding of the protein per cell declined over 3 days; however,
binding was still measureable after 3 days.
To illustrate the binding of PNP-AV to the cell membrane,
MCF-7 cells were fixed, incubated with biotinylated PNP-AV, and
then incubated with streptavidin conjugated Alexa Fluor 488.
Fig. 5 shows confocal microscopy images of the protein bound to
the external surface of the cells with nuclei and plasma membrane
counterstains. It is observed that the binding of PNP-AV (green) is
found only on the plasma membrane (red) but does not completely
cover the membrane.
In vitro Cytotoxicity
The results of the cytotoxicity studies for MCF-7 and MDA-
MB-231 breast cancer cells and non-confluent HAAE-1 endothe-
lial cells are shown in Fig. 6. The cell viability data is shown as a
percentage relative to the untreated control on days 2, 4, and 6.
There was significant cell killing (p,0.001) by treatments for all
three cell lines, with greater than 95% cytotoxicity after 6 days of
treatment for the MCF-7 and non-confluent endothelial cells;
Figure 2. PNP-AV, PNP, AV protein models. Images generated
with The PyMOL Molecular Graphics System, Version 1.2r3pre,
Schro¨dinger, LLC with data files obtained through the Protein Data
Bank Europe. (a) Image of human annexin V generated from the crystal
structure [38]. (b) Image of Escherichia coli PNP [39]. c Mesh image of a
model of PNP-AV hexamer.
doi:10.1371/journal.pone.0076403.g002
Figure 3. MCF-7 dissociation constant binding data. Specific
binding (m) was determined by subtracting total binding (N) in calcium
supplemented medium from nonspecific binding (&) in calcium
deficient medium. Binding was quantified with biotinylated protein
and HRP-conjugated streptavidin, developed with OPD. Data are
presented as mean 6 SE (n= 3).
doi:10.1371/journal.pone.0076403.g003
Table 1. Dissociation constant (Kd) of PNP-AV binding to cells.
Cell line Dissociation constant (Kd) ± SE (n=3)
HAAE-1 18.3 pM 616.4 pM
MCF-7 51.6 pM 618.0 pM
MDA-MB-231 75.3 pM 652.3 pM
doi:10.1371/journal.pone.0076403.t001
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more than 80% cytotoxicity was obtained for the MDA-MB-231
cells after 6 days. For the non-confluent endothelial cells, there
was more cell killing for the treatment with PNP-AV/fludarabine
and 2-fluoroadenine compared to treating with fludarabine only.
For the two breast cancer cell lines, the cell killing by treatment
with fludarabine only, PNP-AV/fludarabine, and 2-fluoroadenine
were similar. Cytotoxicity was also performed using confluent
endothelial HAAE-1 cells, which showed no significant effect on
cell viability (p,0.001) for treatment with fludarabine only or
PNP-AV/fludarabine (data not shown).
Discussion
In this study we were able to produce a recombinant fusion
protein consisting of E. coli purine nucleoside phosphorylase and
human annexin V, while maintaining strong binding capability
and good enzymatic activity. Recombinant PNP production
in other studies has yielded enzyme activities between 27 and
180 U/mg [11]. The PNP-AV activity in the present study was
determined to be 35 U/mg, which corresponds to an activity of
87.5 U/mg when accounting for only the PNP portion of the
fusion and is consistent with the activity of recombinant PNP
produced by other groups.
The in vitro binding studies presented in this paper confirm
strong binding to the membranes of cancer cells and non-confluent
vasculature endothelial cells. Endothelial seeding densities that
lead to non-confluence result in the activation of the endothelial
cells, including HAAE-1 cells, which models the tumor vasculature
[31]. Earlier studies in our laboratory have shown that annexin V
in a fusion protein binds to non-confluent endothelial cells but
does not bind to these cells when they are confluent [21], which
means that non-confluent endothelial cells mimic the PS exposure
of the tumor vasculature; this is consistent with the finding by
others that annexin V binds to phosphatidylserine expressed on
endothelial cells of tumor vasculature, but not normal endothelial
cells [19,20]. The lack of binding of the PNP-AV fusion protein to
confluent endothelial cells was further confirmed in this study
when we found that a Kd value for specific binding could not be
obtained, thus indicating that confluent endothelial cells mimic the
normal vasculature.
The PNP-AV binding was found to be significantly stronger
than AV and AV fusions with cytosine deaminase and L-
methioninase [21,22], possibly because PNP-AV is a hexamer
with six annexin V’s present on each protein; cytosine deaminase
and L-methioninase are a dimer and a tetramer, respectively.
Modeling of the structure of the fusion protein, shown in Fig. 2,
suggests that the annexin V components of the fusion are
accessible and available for binding. Confocal microscopy
confirms that the fusion protein is bound to the cell membrane
Figure 4. PNP-AV binding stability. Bound fusion protein over a
3 day period was quantified for MCF-7 (¤), MDA-MB-231 (m), and
HAAE-1 (&) cell lines. Data are presented as mean 6 SE (n= 3).
doi:10.1371/journal.pone.0076403.g004
Figure 5. PNP-AVmembrane binding visualization. Confocal microscopy of MCF-7 cells confirms the presence of externally bound biotinylated
PNP-AV, with streptavidin-conjugated Alexa Fluor 488 in green (a, e), red CellMask stain of the plasma membrane (b, f), and blue Hoechst 33258 dye
staining of nucleic acids (c, g). Images a-c show the color channels of an x-y confocal image with the composite shown in d. Images e-g show the
color channels of an x-z cross-section of cells with the composite shown in h and the coverslip indicated by the white in each image.
doi:10.1371/journal.pone.0076403.g005
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Figure 6. In vitro cytotoxicity of enzyme prodrug treatment. The effects of fludarabine, 2-fluoroadenine, and fludarabine converted to 2-
fluoroadenine by PNP are shown for (a) non-confluent HAAE-1 cells, (b) MCF-7 cells, and (c) MDA-MB-231 cells. Groups that received PNP-AV were
Enzyme Prodrug Therapy for Cancer
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but does not continuously cover the membrane (Fig. 5). This type
of discontinuous exposure of PS has also been observed by others
for MDA-MB-235 breast cancer cells [32].
This study indicates a significant cytotoxic effect of this enzyme
prodrug system on breast cancer cell lines MCF-7 and MDA-MB-
231 and endothelial cells representative of the tumor vasculature,
non-confluent HAAE-1. A 6-day incubation period is clearly
relevant for the enzyme prodrug treatment for all three cell lines
tested, since the cell viability declined after each 2-day interval in
every case. The enzyme prodrug treatment was particularly
effective for the MCF-7 cancer cells and the non-confluent
endothelial cells, where greater than 95% cytotoxicity was
obtained after 6 days of treatment. The lack of significant effect
on confluent endothelial cells is a further indication that no
binding of the fusion protein had occurred and that confluent
endothelial cells are representative of the normal vasculature; this
is consistent with our previous finding that the cytosine deaminase-
annexin V fusion protein did not bind to confluent endothelial
cells [21].
The in vitro cytotoxic effect of fludarabine alone on breast cancer
cells confirms work in another study that found significant killing
between 2.5 and 10 mM fludarabine, particularly with the MCF-
7 cell line [3]. This could potentially result from active transport
across the cell membrane and an increased capacity to retain
nucleoside analogue triphosphates in tumor cells (see Fig. 1) [33].
Despite the promising results of fludarabine alone, a phase II
clinical trial suggests that this strategy is not sufficient for clinically
advanced breast cancers [34]. Myelosuppression was the major
dose-limiting factor that held fludarabine below effective levels.
The enzyme prodrug approach is a potential improvement over
fludarabine treatment, as the conversion of fludarabine to 2-
fluoroadenine increases the compound’s toxicity, affects dividing
and non-dividing cells, and allows for a bystander killing effect due
to free diffusion across membranes [10]. Thus, intensification of
the cytotoxic effect only at the site of the tumor would allow for a
reduced systemic dose of fludarabine while enhancing treatment
efficacy.
Following administration of the PNP-AV fusion protein in a
clinical treatment, an immune response may occur because of E.
coli PNP being present. To avoid this problem, a human PNP
could be used that has been mutated with two amino acid
substitutions so that it can utilize fludarabine as a substrate [35].
Another approach would be to conjugate the E. coli PNP with
polyethylene glycol (PEG) to reduce or eliminate an immune
response; PNP from E. coli has been successfully PEGylated to
substantially reduce its immunogenicity while maintaining enzyme
activity [36]. Human AV is not expected to induce an
immunogenic response.
In conclusion, we were able to produce a recombinant fusion
protein of PNP-AV that binds and kills breast cancer cells and
endothelial cells that mimic the PS exposure of tumor vasculature
when used in an enzyme prodrug therapy with fludarabine. The
results suggest that this treatment could be useful as a targeted
therapy for breast cancer.
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